Lisa Henss1, Tatjana Scholz1, Christine von Rhein1, Imke Wieters2, Frauke Borgans2, Fabian J Eberhardt2, Kai Zacharowski3, Sandra Ciesek4, Gernot Rohde5, Maria Vehreschild2, Christoph Stephan2, Timo Wolf2, Heike Hofmann-Winkler6, Heinrich Scheiblauer7, Barbara S Schnierle1. 1. Paul-Ehrlich-Institut, Department of Virology, Langen, Germany. 2. Zentrum für Innere Medizin, Infektiologie, Universitätsklinikum Frankfurt, Goethe Universität Frankfurt, Frankfurt am Main, Germany. 3. Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinikum Frankfurt, Frankfurt am Main, Germany. 4. Institut für Medizinische Virologie, Universitätsklinikum Frankfurt am Main, Goethe Universität Frankfurt, Frankfurt am Main, Germany. 5. Medizinische Klinik 1, Pneumologie/Allergologie, Universitätsklinikum Frankfurt-Goethe-Universität, Frankfurt am Main, Germany. 6. Deutsches Primatenzentrum GmbH, Leibniz-Institut für Primatenforschung, Göttingen, Germany. 7. Paul-Ehrlich-Institut, IVD, Langen, Germany.
Abstract
BACKGROUND: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has caused a pandemic with tens of millions of cases and hundreds of thousands of deaths. The infection causes coronavirus disease 2019 (COVID-19), a disease of the respiratory system of divergent severity. In the current study, humoral immune responses were characterized in a cohort of 143 patients with COVID-19 from the University Hospital Frankfurt am Main, Germany. METHODS: SARS-CoV-2-specific-antibodies were detected by enzyme-linked immunosorbent assay (ELISA). SARS-CoV-2 and human coronavirus NL63 neutralization activity was analyzed with pseudotyped lentiviral vectors. RESULTS: The severity of COVID-19 increased with age, and male patients encountered more serious symptoms than female patients. Disease severity was correlated with the amount of SARS-CoV-2-specific immunoglobulin (Ig) G and IgA and the neutralization activity of the antibodies. The amount of SARS-CoV-2-specific IgG antibodies decreased with time after polymerase chain reaction conformation of the infection, and antibodies directed against the nucleoprotein waned faster than spike protein-directed antibodies. In contrast, for the common flu coronavirus NL63, COVID-19 disease severity seemed to be correlated with low NL63-neutralizing activities, suggesting the possibility of cross-reactive protection. CONCLUSION: The results describe the humoral immune responses against SARS-CoV-2 and might aid the identification of correlates of protection needed for vaccine development.
BACKGROUND: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has caused a pandemic with tens of millions of cases and hundreds of thousands of deaths. The infection causes coronavirus disease 2019 (COVID-19), a disease of the respiratory system of divergent severity. In the current study, humoral immune responses were characterized in a cohort of 143 patients with COVID-19 from the University Hospital Frankfurt am Main, Germany. METHODS:SARS-CoV-2-specific-antibodies were detected by enzyme-linked immunosorbent assay (ELISA). SARS-CoV-2 and human coronavirus NL63 neutralization activity was analyzed with pseudotyped lentiviral vectors. RESULTS: The severity of COVID-19 increased with age, and male patients encountered more serious symptoms than female patients. Disease severity was correlated with the amount of SARS-CoV-2-specific immunoglobulin (Ig) G and IgA and the neutralization activity of the antibodies. The amount of SARS-CoV-2-specific IgG antibodies decreased with time after polymerase chain reaction conformation of the infection, and antibodies directed against the nucleoprotein waned faster than spike protein-directed antibodies. In contrast, for the common flu coronavirus NL63, COVID-19 disease severity seemed to be correlated with low NL63-neutralizing activities, suggesting the possibility of cross-reactive protection. CONCLUSION: The results describe the humoral immune responses against SARS-CoV-2 and might aid the identification of correlates of protection needed for vaccine development.
Authors: Priscila M S Castanha; Dylan J Tuttle; Georgios D Kitsios; Jana L Jacobs; Ulisses Braga-Neto; Matthew Duespohl; Sanjay Rathod; Michelle M Marti; Sarah Wheeler; Asma Naqvi; Brittany Staines; John Mellors; Alison Morris; Bryan J McVerry; Faraaz Shah; Caitlin Schaefer; Bernard J C Macatangay; Barbara Methe; Christian A Fernandez; Simon M Barratt-Boyes; Donald Burke; Ernesto T A Marques Journal: J Infect Dis Date: 2022-09-13 Impact factor: 7.759
Authors: Claire T Deakin; Georgina H Cornish; Kevin W Ng; Nikhil Faulkner; William Bolland; Joshua Hope; Annachiara Rosa; Ruth Harvey; Saira Hussain; Christopher Earl; Bethany R Jebson; Meredyth G L L Wilkinson; Lucy R Marshall; Kathryn O'Brien; Elizabeth C Rosser; Anna Radziszewska; Hannah Peckham; Harsita Patel; Judith Heaney; Hannah Rickman; Stavroula Paraskevopoulou; Catherine F Houlihan; Moira J Spyer; Steve J Gamblin; John McCauley; Eleni Nastouli; Michael Levin; Peter Cherepanov; Coziana Ciurtin; Lucy R Wedderburn; George Kassiotis Journal: Med (N Y) Date: 2021-08-14
Authors: Ricardo da Silva Antunes; Suresh Pallikkuth; Erin Williams; Esther Dawen Yu; Jose Mateus; Lorenzo Quiambao; Eric Wang; Stephen A Rawlings; Daniel Stadlbauer; Kaijun Jiang; Fatima Amanat; David Arnold; David Andrews; Irma Fuego; Jennifer M Dan; Alba Grifoni; Daniela Weiskopf; Florian Krammer; Shane Crotty; Michael E Hoffer; Savita G Pahwa; Alessandro Sette Journal: J Infect Dis Date: 2021-07-02 Impact factor: 5.226
Authors: William R Morgenlander; Stephanie N Henson; Daniel R Monaco; Athena Chen; Kirsten Littlefield; Evan M Bloch; Eric Fujimura; Ingo Ruczinski; Andrew R Crowley; Harini Natarajan; Savannah E Butler; Joshua A Weiner; Mamie Z Li; Tania S Bonny; Sarah E Benner; Ashwin Balagopal; David Sullivan; Shmuel Shoham; Thomas C Quinn; Susan H Eshleman; Arturo Casadevall; Andrew D Redd; Oliver Laeyendecker; Margaret E Ackerman; Andrew Pekosz; Stephen J Elledge; Matthew Robinson; Aaron Ar Tobian; H Benjamin Larman Journal: J Clin Invest Date: 2021-04-01 Impact factor: 19.456
Authors: Juliana D Siqueira; Livia R Goes; Brunna M Alves; Ana Carla P da Silva; Pedro S de Carvalho; Claudia Cicala; James Arthos; João P B Viola; Marcelo A Soares Journal: Infect Genet Evol Date: 2021-02-14 Impact factor: 3.342
Authors: Antonio Bertoletti; Clarence C Tam; Nina Le Bert; Hannah E Clapham; Anthony T Tan; Wan Ni Chia; Christine Y L Tham; Jane M Lim; Kamini Kunasegaran; Linda Wei Lin Tan; Charles-Antoine Dutertre; Nivedita Shankar; Joey M E Lim; Louisa Jin Sun; Marina Zahari; Zaw Myo Tun; Vishakha Kumar; Beng Lee Lim; Siew Hoon Lim; Adeline Chia; Yee-Joo Tan; Paul Anantharajah Tambyah; Shirin Kalimuddin; David Lye; Jenny G H Low; Lin-Fa Wang; Wei Yee Wan; Li Yang Hsu Journal: J Exp Med Date: 2021-05-03 Impact factor: 14.307
Authors: Alana L Whitcombe; Reuben McGregor; Alyson Craigie; Alex James; Richard Charlewood; Natalie Lorenz; James Mj Dickson; Campbell R Sheen; Barbara Koch; Shivani Fox-Lewis; Gary McAuliffe; Sally A Roberts; Susan C Morpeth; Susan Taylor; Rachel H Webb; Susan Jack; Arlo Upton; James E Ussher; Nicole J Moreland Journal: Clin Transl Immunology Date: 2021-03-14
Authors: Alyson Craigie; Reuben McGregor; Alana L Whitcombe; Lauren Carlton; David Harte; Michelle Sutherland; Matthew Parry; Erasmus Smit; Gary McAuliffe; James Ussher; Nicole J Moreland; Susan Jack; Arlo Upton Journal: Pathology Date: 2021-05-18 Impact factor: 5.306
Authors: William Morgenlander; Stephanie Henson; Daniel Monaco; Athena Chen; Kirsten Littlefield; Evan M Bloch; Eric Fujimura; Ingo Ruczinski; Andrew R Crowley; Harini Natarajan; Savannah E Butler; Joshua A Weiner; Mamie Z Li; Tania S Bonny; Sarah E Benner; David Sullivan; Shmuel Shoham; Thomas C Quinn; Susan Eshleman; Arturo Casadevall; Andrew D Redd; Oliver Laeyendecker; Margaret E Ackerman; Andrew Pekosz; Stephen J Elledge; Matthew Robinson; Aaron A R Tobian; H Benjamin Larman Journal: medRxiv Date: 2020-12-18